Everjoy Health Group Co., Ltd. (002162.SZ)
CNY 4.12
(-5.72%)
CNY 4.12
(-5.72%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 123.61 Million | 25.87 Million | 153.24 Million | 152.45 Million | 132.14 Million | 135.5 Million |
| Net Income | 48.03 Million | -280.88 Million | 47.76 Million | 57.11 Million | 37.07 Million | 22.4 Million |
| Depreciation & Amortization | 65.91 Million | 71.38 Million | 75.48 Million | 61.06 Million | 67.98 Million | 62.25 Million |
| Deferred income taxes | -9.24 Million | -20.88 Million | -1.96 Million | 3.55 Million | 5.52 Million | 5.38 Million |
| Stock-based compensation | 2.75 Million | - | - | - | - | - |
| Change in working capital | 9.22 Million | -74.88 Million | -16.43 Million | -10.2 Million | -36.02 Million | -560.02 Thousand |
| Other non-cash items | 437.35 Thousand | 310.25 Million | 46.42 Million | 44.48 Million | 63.1 Million | 51.41 Million |
| Investing Cash Flow | 80.38 Million | -83.77 Million | -56.75 Million | -61.1 Million | 178.45 Thousand | -148.72 Million |
| Investments in PPE | -49.51 Million | -39.5 Million | -34.15 Million | -29.03 Million | -21.99 Million | -58.65 Million |
| Acquisitions | 86.57 Million | 6.77 Million | 1.46 Million | 3.23 Million | 1.00 | -59.08 Million |
| Investment purchases | -115 Million | -182.09 Million | -658.32 Million | -817.55 Million | -951.55 Million | -1.1 Billion |
| Sales/Maturities of investments | 137.58 Million | 131.05 Million | 623.38 Million | 778.83 Million | 968.39 Million | 1.07 Billion |
| Other Investing Activities | 20.73 Million | 0.11 | 10.87 Million | 3.4 Million | 5.32 Million | 3.89 Million |
| Financing Cash Flow | -129.65 Million | -50.64 Million | -5.78 Million | -129.69 Million | -121.49 Million | 21.74 Million |
| Debt repayment | -441.96 Million | -710.33 Million | -506.29 Million | -686.48 Million | -716.35 Million | -975.7 Million |
| Dividends payments | -24.5 Million | -23.62 Million | -29.41 Million | -37.82 Million | -46.94 Million | -46.27 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 16.81 Million | 683.31 Million | 529.92 Million | 594.61 Million | 641.8 Million | 1.04 Billion |
| Accounts receivables | -45.67 Million | -65.81 Million | -6 Million | -192.92 Million | -67.78 Million | -28.66 Million |
| Accounts payables | 15.35 Million | -21.14 Million | -27.94 Million | 153.82 Million | 38.66 Million | 23.61 Million |
| Inventory | 48.79 Million | 32.96 Million | 19.47 Million | 25.33 Million | -12.41 Million | -884.52 Thousand |
| Other working capital | -9.24 Million | -20.88 Million | -1.96 Million | 3.55 Million | 5.52 Million | 324.49 Thousand |
| Cash at beginning of period | 141.16 Million | 249.6 Million | 158.94 Million | 197.46 Million | 186.59 Million | 178.07 Million |
| Cash at end of period | 215.53 Million | 141.16 Million | 249.6 Million | 158.94 Million | 197.46 Million | 186.59 Million |
| Capital Expenditure | -49.51 Million | -39.5 Million | -34.15 Million | -29.03 Million | -21.99 Million | -58.65 Million |
| Effect of forex changes on cash | 20.54 Thousand | 106.84 Thousand | -50.35 Thousand | -164.17 Thousand | 43.8 Thousand | -9941.98 |
| Net cash flow / Change in cash | 74.36 Million | -108.44 Million | 90.65 Million | -38.51 Million | 10.86 Million | 8.52 Million |
| Free Cash Flow | 74.09 Million | -13.62 Million | 119.08 Million | 123.42 Million | 110.15 Million | 76.85 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -35.5 Million | 15.44 Million | -13.01 Million | -58.78 Million | 48.03 Million | -59.69 Million |
| Depreciation & Amortization | - | 18.44 Million | 18.44 Million | 19.34 Million | 65.91 Million | -32.34 Million |
| Deferred income taxes | - | - | - | -8.63 Million | -9.24 Million | - |
| Stock-based compensation | - | - | - | 2.75 Million | 2.75 Million | - |
| Change in working capital | - | 57.27 Million | - | 5.87 Million | 9.22 Million | -5.47 Million |
| Other non-cash items | 89.96 Million | 37.66 Million | -40.93 Million | 109.23 Million | 437.35 Thousand | 137.47 Million |
| Investing Cash Flow | -57.08 Million | -28.49 Million | -8.74 Million | 12.77 Million | 80.38 Million | -12.75 Million |
| Investments in PPE | -11.14 Million | -8.49 Million | -8.24 Million | -15.32 Million | -49.51 Million | -7.58 Million |
| Acquisitions | - | - | - | 92.27 Million | 86.57 Million | -5.22 Million |
| Investment purchases | -804 Thousand | -41 Million | -46.5 Million | -28 Million | -115 Million | - |
| Sales/Maturities of investments | 24.85 Million | 41 Million | 46 Million | -36.18 Million | 137.58 Million | - |
| Other Investing Activities | -70 Million | -20 Million | -474.87 Thousand | 0.06 | 20.73 Million | 46 Thousand |
| Financing Cash Flow | 18.91 Million | 5.54 Million | -11.98 Million | -7.77 Million | -129.65 Million | -80.87 Million |
| Debt repayment | -30.65 Million | -40.25 Million | -3.73 Million | -66.93 Million | -441.96 Million | -133.75 Million |
| Dividends payments | -6.23 Million | -7.23 Million | -5.76 Million | -4.89 Million | -24.5 Million | -5.76 Million |
| Common Stock Repurchased | - | -25.18 Million | - | -15.75 Million | - | - |
| Common Stock Issuance | -1.02 Million | 1.02 Million | - | - | - | - |
| Other Financing Activities | -5.49 Million | -24.93 Million | -8.25 Million | -30.94 Million | 16.81 Million | 58.63 Million |
| Accounts receivables | - | 50.88 Million | - | -45.67 Million | -45.67 Million | -6.83 Million |
| Accounts payables | - | - | - | - | 15.35 Million | - |
| Inventory | - | 6.39 Million | - | 48.79 Million | 48.79 Million | 1.35 Million |
| Other working capital | - | - | - | 2.75 Million | -9.24 Million | - |
| Cash at beginning of period | 152.56 Million | 266.22 Million | 346.92 Million | 140.75 Million | 141.16 Million | 194.43 Million |
| Cash at end of period | 167.25 Million | 194.41 Million | 266.22 Million | 215.53 Million | 215.53 Million | 140.75 Million |
| Capital Expenditure | -11.14 Million | -8.49 Million | -8.24 Million | -15.32 Million | -49.51 Million | -7.58 Million |
| Effect of forex changes on cash | -4736.27 | 3052.67 | 889.33 | -7397.85 | 20.54 Thousand | -4801.02 |
| Net cash flow / Change in cash | 14.68 Million | -71.8 Million | -80.69 Million | 74.77 Million | 74.36 Million | -53.68 Million |
| Free Cash Flow | 43.32 Million | 26.16 Million | -62.19 Million | 54.46 Million | 74.09 Million | 32.36 Million |
CNH
300451
2M6
AARTIPHARM
SELAN
UNH